A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis
Luc Dupuis,
Reinhard Dengler,
Michael T Heneka,
Thomas Meyer,
Stephan Zierz,
Jan Kassubek,
Wilhelm Fischer,
Franziska Steiner,
Eva Lindauer,
Markus Otto,
Jens Dreyhaupt,
Torsten Grehl,
Andreas Hermann,
Andrea S Winkler,
Ulrich Bogdahn,
Reiner Benecke,
Bertold Schrank,
Carsten Wessig,
Julian Grosskreutz,
Albert C Ludolph and
the GERP ALS Study Group
PLOS ONE, 2012, vol. 7, issue 6, 1-7
Abstract:
Background: Pioglitazone, an oral anti-diabetic that stimulates the PPAR-gamma transcription factor, increased survival of mice with amyotrophic lateral sclerosis (ALS). Methods/Principal Findings: We performed a phase II, double blind, multicentre, placebo controlled trial of pioglitazone in ALS patients under riluzole. 219 patients were randomly assigned to receive 45 mg/day of pioglitazone or placebo (one: one allocation ratio). The primary endpoint was survival. Secondary endpoints included incidence of non-invasive ventilation and tracheotomy, and slopes of ALS-FRS, slow vital capacity, and quality of life as assessed using EUROQoL EQ-5D. The study was conducted under a two-stage group sequential test, allowing to stop for futility or superiority after interim analysis. Shortly after interim analysis, 30 patients under pioglitazone and 24 patients under placebo had died. The trial was stopped for futility; the hazard ratio for primary endpoint was 1.21 (95% CI: 0.71–2.07, p = 0.48). Secondary endpoints were not modified by pioglitazone treatment. Pioglitazone was well tolerated. Conclusion/Significance: Pioglitazone has no beneficial effects on the survival of ALS patients as add-on therapy to riluzole. Trial Registration: Clinicaltrials.gov NCT00690118.
Date: 2012
References: View complete reference list from CitEc
Citations:
Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0037885 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 37885&type=printable (application/pdf)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0037885
DOI: 10.1371/journal.pone.0037885
Access Statistics for this article
More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().